Published on 17 Sep, 2026
Updated on 17 Sep, 2026
Fatty liver may vary from person to person and change over time, but not everyone with steatosis develops fibrosis. Fatty liver can range from simple fat buildup to inflammation and liver scarring; the same condition does not progress in the same way for everyone. Some people may remain at the fatty liver stage, while others can develop inflammation and fibrosis.
It is the stage where fat builds up in the liver and causes no damage or just mild discomfort. It is often the first stage of fatty liver.
At this stage, there is no inflammation, swelling, or cell destruction. Many people do not notice any symptoms at this stage. Having steatosis does not always mean that the liver is scarred. Fat and fibrosis are separate.
In this stage, the excess fat accumulation is accompanied by inflammation and liver cell injury. If this stage continues for a long time, the repeated injury can trigger the formation of scar tissue. Not everyone with fatty liver develops MASH/NASH.
MASH (Metabolic dysfunction-associated steatohepatitis), previously known as NASH (nonalcoholic steatohepatitis), is a part of MASLD (metabolic dysfunction-associated steatotic liver disease).
.webp)
These three terms are related but mean different things in fatty liver disease:
It is the immune system's active response to injured liver cells; it occurs when liver cells are repeatedly irritated because white blood cells rush to the liver, causing swelling, irritation, and ongoing cell damage. In MASH/NASH, excess fat in the liver is accompanied by inflammation and liver-cell damage. If the inflammation continues, it can lead to further liver injury. Liver inflammation is fully reversible if you reduce excess fat, improve diet, and control metabolic health.
When the liver tries to repair repeated damage, it can produce extra connective tissue; this tissue builds up in the liver and replaces healthy tissue. The early accumulation of collagen and protein which are temporary repair tissue made to cover dying liver cells. It is commonly known as scar tissue, and it is generally reversible if the underlying inflammation stops.
Fibrosis is the medical term for this build-up of scar tissue in the liver. It is the massive organized build-up of hard scar tissue that starts to replace and suffocate normal liver architecture. It happens when chronic inflammation turns temporary patches into dense bands of scar tissue, decreasing blood flow and stiffening the organ. Early fibrosis is reversible if the root cause is treated, but advanced fibrosis is permanent.
Inflammation and fibrosis are not the same; inflammation can contribute to fibrosis, while fibrosis refers specifically to the resulting scar tissue.
Not everyone with fatty liver progresses to MASH/NASH or fibrosis. It is primarily driven by metabolic, genetic, and lifestyle factors. The risk can be higher when certain factors are present:
Professionals use a combination of blood-based biomarker scores, non-invasive imaging, and histological staging to assess progression from fatty liver to MASH, NASH, or advanced fibrosis.
Blood Tests And Biomarkers Include:
Early Yakrit roga (liver disease) such as MASH/NASH is often a silent condition that does not have any noticeable symptoms in the initial stages. The early stages are easily overlooked, and as ongoing inflammation worsens, more serious red flags emerge. These are indicators that you should get professional help if you have:
MASH and liver fibrosis risk can be managed with gradual weight loss, dietary adjustments, and an active emphasis on improving metabolic health.
According to Ayurveda, MASH and liver fibrosis are metabolic crises, occurring from the accumulation of Ama (toxins) due to imbalance in agni (digestive fire) and pathological buildup of Kapha and Meda Dhatu in the Yakrit (liver). Ayurvedic risk reduction focuses on progressive detoxification, restoring digestive fire, and clearing Srotas (channels).
These treatments should be undertaken under professional guidance, and consuming these herbs without consulting an Ayurvedic physician or overdosing can affect your health.
Fatty liver disease is better understood as a spectrum rather than a fixed sequence that everyone follows. Some people have liver fat without any liver injury, while other develops innflammation, fibrosis, and eventually cirrhosis.
Progression stages of fatty liver disease:
MASLD is commonly seen in people with metabolic risk factors such as insulin resistance, type-2 diabetes, obesity, and high triglycerides.
At this stage, liver fat is present. There may be little or no inflammation and no symptoms. Fat accumulation can be improved if metabolic causes can be addressed.
Excess fat accumulation accompanied by inflammation and liver cell injury is known as MASH/NASH.
When liver tissues are repeatedly damaged, the liver starts to produce connective tissue. If further damage continues, scar tissue accumulates.
If fibrosis becomes more extensive, the liver’s normal architecture becomes increasingly distorted. Extreme cases turn into cirrhosis, which can even lead to liver failure.
The amount of fat cannot tell everything. Fibrosis is particularly important when assessing the risk of future liver-related complications. These conditions can put your overall health at risk. If you have these conditions, you should seek professional guidance. For Ayurvedic guidance, contact Jiva Ayurveda ASAP.
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review - PubMed
No, many people with fatty liver do not develop MASH or significant liver damage.
MASLD generally refers to fat accumulation linked with metabolic dysfunction, while MASH involves fat accumulation, inflammation, and liver-cell injury.
Yes, particularly in the early stages. Addressing the underlying metabolic factors, such as improving diet, physical activity, and gradual weight loss, can reduce fat stored in the liver and improve inflammation.
Yes, NASH is the older term, while MASH is the new term.
Doctors may use blood-based tests such as FIB-4, FibroScan, other imaging tests like ultrasound, or sometimes a liver biopsy.
